✦ LIBER ✦

Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer

✍ Scribed by Yu-Yun Shao; Wen-Yi Shau; Zhong-Zhe Lin; Ho-Min Chen; Raymond Kuo; James Chih-Hsin Yang; Mei-Shu Lai

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gefitinib as first-line, compassionate u

✍ Argiris, Athanassios; Mittal, Namrata 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Gefitinib as First-line Therapy for Adva

✍ Cheng-Ta Yang; Jen-Yu Hung; Chun-Liang Lai; Hsin-Chia Hung; Yung-Fa Lai; Meng-Ch 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 312 KB

Erlotinib and pemetrexed as maintenance

✍ Qi, Wei-Xiang; Tang, Li-na; He, Ai-na; Shen, Zan; Lin, Feng; Yao, Yang 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 449 KB

50 IMPLEMENTATION OF ADHERENCE TO ERLOTI

✍ V. Gebbia; G. Bellavia; P. Russo; G.L. Banna; F. Ferraù; P. Tralongo; N. Borsell 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Antiangiogenic agents as second-line the

✍ Karen L. Reckamp 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 370 KB

Third-line therapy for advanced non-smal

✍ Zhengbo Song; Yongfeng Yu; Zhiwei Chen; Shun Lu 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 387 KB